Time of Update: 2022-05-28
According to the latest announcement on the official website of the Center for Drug Evaluation (CDE) of the China National Medical Products Administration, the QGE031 injection submitted by Novartis has obtained the implied license for clinical trials, and the indication is chronic induced urticaria .
Development and initial validation of the Sjögren's Syndrome Response Assessment Tool (STAR): a composite score for assessing treatment effects in primary Sjögren's syndrome
Time of Update: 2022-05-14
The NECESSITY (New Clinical Endpoints in Primary Sjögren's Syndrome: Interventional Trials Based on Patient Stratification) Consortium (https:// includes pSS experts from academia, pharmaceutical industry and patient groups, The experts aimed to develop a new composite responder index, Sjögren's Response Assessment Tool (STAR) .
Reduce the risk of hospitalization or death by 90% Pfizer announces latest data on oral anti-corona therapy
Time of Update: 2022-01-11
In a phase 2/3 clinical trial for the treatment of COVID-19 patients who are at high risk of developing severe COVID-19, the final analysis results show that Paxlovid can reduce the risk of hospitalization or death by nearly 90% .
Alzheimer Dementia: Periodontitis, or suggest the possibility of dementia
Time of Update: 2021-08-02
And by including GANI_MED's treated subjects and SHIP-TREND's untreated subjects into the quasi-experimental design, the relationship between periodontal treatment and AD preclinical stage was studied .
World Health Organization: Hepatitis
Time of Update: 2021-06-29
The risk factors are: · Poor environmental sanitation · Lack of safe water · Injecting drugs · Living with an infected person · Sexual partners of patients with acute hepatitis A · Traveling to high-endemic areas without vaccinations .
Bristol-Myers Squibb partners with Xencor to extend COVID-19 antibody half
Time of Update: 2021-06-03
Bristol Myers Squibb will use Xencor's technology to extend the half-life of SARS-CoV-2 neutralizing monoclonal antibody combination therapy.
2. Bristol Myers Squibb: Xencor and Bristol Myers Squibb Enter License Agreement for Use of Xtend™ XmAb® Technology in SARS-CoV-2 Neutralizing Monoclonal Antibody Combination for the Treatment of COVID-19
Experts summarize the key points of antiviral treatment for HBV-related hepatocellular carcinoma patients at once
Time of Update: 2021-05-22
For HBV-related HCC patients, antiviral therapy can not only inhibit virus replication and reactivation, improve liver function, and increase surgical safety It can also reduce the reactivation of HBV caused by anti-tumor therapy and reduce the incidence of end-stage liver disease events.
3 minutes to focus on blood pressure management in patients with acute ischemic stroke and heart disease|Guideline consensus
Time of Update: 2021-04-18
➤Recommendations for acute ischemic stroke combined with chronic heart failure: The average arterial pressure can be reduced by 15% from the baseline level within the first 24 hours after AIS; the blood pressure can be gradually controlled to a level that the patient's heart function can tolerate according to the cerebral perfusion status.
JAMA Surg: The screening rate for primary aldosteronism in hypertensive patients is less than 1
Time of Update: 2021-04-16
PA screening rate and positive rate in hypertensive populationThe study found that among adults with hypertension in Alberta, Canada, less than 1% of patients with primary aldosteronism are expected to be formally diagnosed and treated.
Allogeneic stem cell therapy! Takeda Darvadstrocel Japan applied for listing
Time of Update: 2021-03-10
Takeda recently announced that it has submitted an application to Japan's Ministry of Health, Labour and Labour (MHLW) to produce and sell Darvadstrocel (development code: Cx601) for the treatment of complex fistula in adult patients with in activity/mild active tube crohn's disease (CD).
NovarceEntresto's treatment of HFpEE heart failure has been approved
Time of Update: 2021-03-07
(Pharmaceutical Rubik's Cube) Howson introduced first in class oral antifungal drugs on February 17, Scynexis announced a strategic cooperation agreement with Howson Pharmaceuticals to grant the latter exclusive rights in the development and commercialization of ibrexafungerp in Greater China, including Hong Kong, Macau and Taiwan.
Academician Liu Changxiao: Chinese Biomedicine Enters the "Fast Track
Time of Update: 2021-01-29
From the publication of the whole genome sequence of the new coronavirus to the research and development of the viral nucleic acid testing kit, from the development of antiviral drugs to the listing of the new coronavirus vaccine, Chinese scientists have always adhered to the front line of anti-epidemic, and actively promoted China's biopharmaceutical industry into the "fast lane".
New drug for special dermatitis! Otsuka outside the PDE4 inhibitor defamilast applied for listing, Pfizer similar products Shutanming has been listed in China
Time of Update: 2020-10-14
currently, Pfizer is also selling Eucrisa (Chinese, a nonsteroidal PDE4 inhibitor-type AD drug with a generic name: crisaborole, creborole, 2% ointment, approved for sale in December 2016 for the treatment of mild to moderate specialty dermatitis (AD) in children and adults aged ≥2 years.
The June 2020 issue of Cell had to look at highlights
Time of Update: 2020-08-01
Cell: Structurally revealing the human antibody characteristics associated with SARS-CoV-2 sting proteins doi: 10.1016/j.cell.2020.06.025 in a new study, researchers from the California Institute of Technology and Rockefeller University described the recognition of polyclonal G G and their Fab fragments from the plasma of COVID-19 rehabilitation people for the coronavirus S protein.
It was found that the new technology of bacterial comminution could resist the super resistant bacteria
Time of Update: 2020-02-24
Researchers have developed new bactericidal techniques using liquid metals, which may be the answer to the fatal problem of antibiotic resistance The technology uses nanoparticles of magnetic liquid m